Form 4: Glaukos Corp Executive Joseph E. Gilliam Reports Stock Transactions

Joseph E. Gilliam, President & COO of Glaukos Corporation, reports acquisition and disposal of common stock and stock options related to vesting of restricted stock units and achievement of operational targets.

Summary

• On March 13, 2025, Joseph E. Gilliam, President & COO of Glaukos Corporation, acquired 3,888 shares of common stock related to restricted stock units granted on March 18, 2021, due to the achievement of certain operational targets.
• 50% of these shares will vest in May 2025, and the remaining 50% in February 2026.
• He also acquired 5,829 shares of common stock related to restricted stock units granted on March 14, 2024, which vested and were delivered on March 13, 2025, also due to the achievement of operational targets.
• Additionally, 18,116 restricted stock units were granted, vesting over a four-year period.
• On March 17, 2025, 1,028 shares were withheld by the Issuer for tax obligations related to the vesting of restricted stock units granted on March 14, 2024, at a price of $102.19.
• He also acquired 13,271 shares via stock options granted on March 24, 2022, due to the achievement of operational targets.
• Following these transactions, Gilliam beneficially owns 128,010 shares of common stock and 35,713 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects positive performance as operational targets were met, leading to vesting of equity awards. However, it's a routine filing, so the sentiment is moderately positive.

Positives

• The achievement of operational targets triggered the vesting of restricted stock units and stock options, indicating positive performance for Glaukos Corporation.
• The vesting of shares and options incentivizes the executive to continue driving company performance.

Negatives

• The withholding of 1,028 shares for tax obligations reduced the number of shares directly received by the reporting person.

Risks

• Future vesting of restricted stock units and stock options is contingent on continued achievement of operational targets.
• Fluctuations in the stock price could impact the value of the vested shares and options.

Future Outlook

The document indicates future vesting dates for restricted stock units in May 2025 and February 2026, contingent on continued employment and potentially further achievement of operational targets.

Management Comments

• The Compensation Committee determined that certain operational targets had been achieved, leading to the vesting of restricted stock units and stock options.

Industry Context

Vesting of equity awards based on performance metrics is a common practice in the pharmaceutical and medical device industry to align executive compensation with company performance and shareholder value.

Comparison to Industry Standards

• Companies like Alcon, Johnson & Johnson, and Bausch + Lomb also utilize performance-based equity compensation for their executives.
• The specific operational targets and vesting schedules vary depending on the company's strategic goals and industry benchmarks.
• Glaukos's approach of using multi-year performance periods and operational targets is consistent with industry best practices for long-term incentive plans.

Stakeholder Impact

• Shareholders may view the vesting of equity awards positively, as it indicates that the company is achieving its operational goals.
• Employees may be motivated by the potential for future equity awards based on performance.

Next Steps

• Vesting of remaining restricted stock units in May 2025 and February 2026.
• Continued monitoring of Glaukos Corporation's performance against operational targets.

Key Dates